Published in PLoS One on June 12, 2014
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
AIDS-associated non-Hodgkin lymphoma. Lancet (1991) 3.20
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer (2004) 2.98
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res (2008) 2.46
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer (2010) 1.75
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS (2001) 1.72
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS (2008) 1.60
Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am (2003) 1.55
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood (2000) 1.52
B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev (2011) 1.41
Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol (2006) 1.40
Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst (1996) 1.31
Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol (2003) 1.30
Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol (2006) 1.23
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood (2009) 1.20
B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS (2000) 1.20
The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother (2005) 1.17
Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity. Am J Pathol (1998) 1.15
Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene (2001) 1.08
AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol (2002) 1.01
Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev (2012) 1.01
Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma. AIDS Res Treat (2010) 1.01
AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer (2001) 1.01
Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS One (2012) 1.00
Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis (2005) 0.98
Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas. Cancer Res (1999) 0.96
A comparative study of normal B cells and the EBV-positive Burkitt's lymphoma cell line, Raji, as activators of the complement system. Scand J Immunol (1997) 0.95
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol (2011) 0.94
Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev (1999) 0.94
Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma. AIDS (2005) 0.93
CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res (2004) 0.92
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol (2012) 0.91
Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS (2010) 0.90
Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev (2013) 0.89
Differential gene expression in B-cell non-Hodgkin's lymphoma of SIV-infected monkey. AIDS Res Hum Retroviruses (2000) 0.88
IFN-λ inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production. Antiviral Res (2012) 0.85
Pathogenesis of HIV-associated non-Hodgkin lymphoma. Curr HIV Res (2004) 0.85
Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood (2004) 0.80
Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients. J Clin Immunol (2012) 0.79
CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells. J Immunol (2007) 0.79
Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen (2011) 0.79
Evidence that immunoglobulin specificities of AIDS-related lymphoma are not directed to HIV-related antigens. Blood (2000) 0.78
Azothymidine and interferon-alpha are active in AIDS-associated small non-cleaved cell lymphoma but not large-cell lymphoma. Lancet (1996) 0.77
Role of gelatinases (MMP-2 and MMP-9), TIMP-1, vascular endothelial growth factor (VEGF), and microvessel density on the clinicopathological behavior of childhood non-Hodgkin lymphoma. Pediatr Hematol Oncol (2008) 0.77
Modulation of the systemic inflammatory response by recombinant human interleukin-11: a prospective randomized placebo controlled clinical study in patients with hematological malignancy. Clin Immunol (2006) 0.77
Update: cancer risk in persons with HIV/AIDS in the era of combination antiretroviral therapy. AIDS Read (2000) 0.77
Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma. Pediatr Hematol Oncol (2008) 0.77
Current issues in the biology of AIDS-related lymphoma. HIV Med (2001) 0.76